Clinical use of C-peptide and β-cell specific autoantibodies during gestational diabetes mellitus
Gestational diabetes mellitus (GDM) confers a risk for developing type 2 diabetes later in life, but the risk of developing type 1 diabetes is also increased. In this study we have evaluated the clinical use of C-peptide and β-cell specific autoantibodies during pregnancy with GDM as predictors for later development of diabetes. C-peptide levels were measured 2 hours after glucose intake in pregn
